# Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

> **NCT07723261** · — · RECRUITING · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 70 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07723261
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2029-03-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723261, "Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07723261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*